Search

Displaying results 3661 - 3670 of 7603 in total
  1. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.

  2. Drug

    Cloprednol

    go.drugbank.com/drugs/DB13843
    Investigational

    Cloprednol is a synthetic glucocorticoid that has been investigated for use in the treatment of asthma. [A31775,A31776]

    Categories: Corticosteroids for Systemic Use, Corticosteroids for Systemic Use, Plain
  3. Drug

    ICA-105665

    go.drugbank.com/drugs/DB06089
    Investigational

    ICA-105665 is a novel small molecule compound for the treatment of epilepsy.

  4. Drug

    Aceclofenac

    go.drugbank.com/drugs/DB06736
    Approved

    It is reported to have a higher anti-inflammatory action or at least comparable effects than conventional NSAIDs in double-blind studies [A19667, A19668, A19670].

    Categories: Topical Products for Joint and Muscular Pain, Antiinflammatory Preparations, Non-Steroids for Topical Use
  5. Drug

    Plumbagin

    go.drugbank.com/drugs/DB17048
    Investigational

    Plumbagin is a compound investigated for its anticancer activity. It has been found that it inactivates the Akt/NF-kB, MMP-9 and VEGF pathways.[A253102]

    Categories: Hormonal Contraceptives for Systemic Use, Compounds used in a research, industrial, or household setting
  6. Drug

    Solabegron

    go.drugbank.com/drugs/DB06190
    Investigational

    Solabegron (GW-427,353) is a selective β3 adrenoceptor agonist being developed for the treatment of overactive bladder and irritable bowel syndrome.

    Categories: Drugs for Urinary Frequency and Incontinence
  7. Drug

    Gadoversetamide

    go.drugbank.com/drugs/DB00538
    Approved

    Gadoversetamide, marketed under the trade name OptiMARK, is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver.

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179] … [L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Omidenepag isopropyl

    go.drugbank.com/drugs/DB15071
    Approved

    [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl. … [A253263,A253268] Prostanoid FP receptor agonists (FP agonists), such as [latanoprost], are part of the first-line therapy for ocular hypertension and primary open-angle glaucoma; however, not all patients

  10. Drug

    Sofpironium

    go.drugbank.com/drugs/DB19325
    Approved

    [L51108,L51109] Sofpironium bromide (Sofdra) was approved by the FDA in June 2024 for the topical treatment of primary axillary hyperhidrosis. … [A264153] Sofpironium is rapidly converted to a less active metabolite, BBI-4010, after exerting its activity, thereby limiting the incidence and/or severity of systemic anticholinergic effects.